Houston, TX, October 27th, 2022 – Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi’s SET2,3TM test for use in the I-SPY 2 TRIAL for patients with locally advanced breast cancer. The SET2,3TM test helps to determine which patients with HR+ tumors will benefit from endocrine therapy. Those patients whose […]
Uncategorized
Delphi DiagnosticsTM Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037
Patents recently issued in the US and allowed in Japan provide additional coverage for the company’s proprietary SETTM technologies for patients with HR+HER2- breast cancer and strengthens the company’s intellectual property portfolio. Houston, TX, September 22, 2022 – Delphi DiagnosticsTM Inc. today announced that the United States Patent and Trademark Office has issued US11,459,617 on […]
SET2,3TM Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022
For patients diagnosed with ER+ breast cancer and low endocrine sensitivity (a Low SET2,3 index), dose-dense chemotherapy was associated with superior disease-free survival (DFS) and overall survival (OS) outcomes when compared to non-dose-dense regimens. Houston, TX, June 13 2022 – Delphi Diagnostics Inc. announced today the inclusion of Delphi’s proprietary Sensitivity to Endocrine Therapy test, […]